3 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.
October 2023 in “Benha Journal of Applied Sciences” Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
July 2024 in “Journal of Investigative Dermatology”
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.
Both treatments for localized alopecia areata are equally effective.
2 citations
,
June 2025 in “Journal of Investigative Dermatology”
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
August 2025 in “Saudi Pharmaceutical Journal” The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.
15 citations
,
May 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
5 citations
,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
11 citations
,
May 2015 in “Stem Cells Translational Medicine” Megestrol acetate helps fat-derived stem cells grow, move, and turn into fat cells through a specific receptor.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
60 citations
,
December 2020 in “Stem Cell Research & Therapy” ASC-CM is more effective than EV for treating osteoarthritis.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.